The Ratings Game: Drug maker ChemoCentryx shares rocket on blockbuster potential in rare autoimmune disease

admin 5 years ago No Comments

This post was originally published on this site

A set of conclusive findings from a late-stage clinical trial testing ChemoCentryx Inc.’s experimental vasculitis treatment surprised company executives and investors, who now say they are bullish on the sales and pipeline potential of avacopan.

Prev Article Next Article

The Wall Street Journal: Uber, DoorDash, Grubhub sue New York City over cap on fees

admin September 10, 2021

Need to Know: Return of March panic is the biggest risk to the S&P 500 right now. Here’s the trigger

admin July 2, 2020

Futures Movers: Oil ends sharply lower as traders fear slowdown will weigh on demand

admin August 1, 2022

U.K. house prices surge to all-time high in August

admin September 2, 2020

NerdWallet: How to buy a house even without down payment help from your family

admin October 8, 2019

Market Snapshot: U.S. stock futures hover around records after calm reaction to Fed’s taper plan

admin November 4, 2021

About The Author

admin

in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

By signing up above you will receive the Daily Buzz Offers newsletter and 3rd party advertisements. Expect up to 5 messages per week from us. You can unsubscribe at any time at the bottom of any of our emails.

Related Posts

About The Author

admin